(S043) Changes in Quality of Life After Radiation Therapy for Localized Prostate Cancer After Dissemination of Intensity-Modulated Radiation Therapy

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

External beam radiotherapy during an era after IMRT has become widespread is associated with improved HRQOL measures among prostate cancer patients compared with the era prior to IMRT dissemination.

Elyn H. Wang, Shiyi Wang, Pamela Soulos, Ronald Chen, Cary P. Gross, James B. Yu; Yale University School of Medicine; University of North Carolina School of Medicine

PURPOSE: Although intensity-modulated radiation therapy (IMRT) has replaced three-dimensional conformal radiotherapy (3D-CRT) to become the dominant form of external beam radiation therapy (EBRT) for prostate cancer, it is unclear whether this change in practice has been associated with improved patient outcomes. To estimate the impact of IMRT on health-related quality of life (HRQOL), we examined the HRQOL of elderly patients who had undergone EBRT during two eras: 1998–2001, when 3D-CRT was the standard of care for EBRT, and 2006–2009, when IMRT became the dominant form of EBRT.

METHODS: The Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey was used to obtain HRQOL measurements of Medicare beneficiaries who had received external beam radiotherapy for nonmetastatic prostate cancer and control subjects without cancer.

Control subjects during each era were matched 10:1 by use of propensity scores estimated from demographics and comorbid medical conditions. A total of 90 patients during the early era and 75 patients during the late era had eligible surveys both before and after treatment. Descriptive statistics and random effects linear regression were used to compare HRQOL between cancer patients and matched controls during the two eras. Area under the curve (AUC) was calculated to determine quality-adjusted life-years (QALYs) gained.

RESULTS: During the first 2 years after treatment, patients who were treated in the late era had 0.19 more QALYs compared with patients treated in the early era, relative to matched noncancer controls. Additionally, health utility and mental component scores at follow-up among cases during the early era declined significantly compared with controls, whereas they were similar between cases treated in the late era and their controls (P = .02 for difference in change in health utility and mental component scores between cases and controls during early vs late era).

CONCLUSIONS: External beam radiotherapy during an era after IMRT has become widespread is associated with improved HRQOL measures among prostate cancer patients compared with the era prior to IMRT dissemination.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content